Redhill Biopharma (Redhill Biopharma) Net Issuance of Preferred Stock : $0.00 Mil (TTM As of Jun. 2023)

View and export this data going back to 2013. Start your Free Trial

What is Redhill Biopharma Net Issuance of Preferred Stock?

A company may raise cash from issuing new preferred shares. It can also use cash to buy back preferred shares.

Redhill Biopharma's net issuance of preferred for the three months ended in Jun. 2023 was $0.00 Mil. The number is 0, which means that Redhill Biopharma has paid equal amouunt of cash to buy back preferred shares to the amount it received for issuing preferred shares quarterly.

Redhill Biopharma's net issuance of preferred for the trailing twelve months (TTM) ended in Jun. 2023 was $0.00 Mil.

Redhill Biopharma Net Issuance of Preferred Stock Historical Data

The historical data trend for Redhill Biopharma's Net Issuance of Preferred Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Redhill Biopharma Net Issuance of Preferred Stock Chart

Redhill Biopharma Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Net Issuance of Preferred Stock

Get a 7-Day Free Trial

Redhill Biopharma Quarterly Data
	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Dec23
Net Issuance of Preferred Stock	Get a 7-Day Free Trial															-	-	-	-	-

Redhill Biopharma Net Issuance of Preferred Stock Calculation

A company may raise cash from issuing new preferred shares. It can also use cash to buy back preferred shares. If this number is positive, it means that the company has received more cash from issuing preferred shares than it has paid to buy back preferred shares. If this number is negative, it means that company has paid more cash to buy back preferred shares than it has received for issuing preferred shares.

Net Issuance of Preferred Stock for the trailing twelve months (TTM) ended in Jun. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

Redhill Biopharma Net Issuance of Preferred Stock Related Terms

Thank you for viewing the detailed overview of Redhill Biopharma's Net Issuance of Preferred Stock provided by GuruFocus.com. Please click on the following links to see related term pages.

Redhill Biopharma (Redhill Biopharma) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Redhill Biopharma Ltd (NAS:RDHL) » Definitions » Net Issuance of Preferred Stock

Comparable Companies

Traded in Other Exchanges

2RH0:Germany 2RH0:Germany

Address

21 Ha’arba’a Street, Tel Aviv, ISR, 6473921

Website

https://www.redhillbio.com

Redhill Biopharma Ltd is a specialty biopharmaceutical company focused on gastrointestinal diseases. The company promotes gastrointestinal drugs, including Movantik for opioid-induced constipation in adults, Talicia for the treatment of Helicobacter pylori infection in adults, and Aemcolo for the treatment of travelers' diarrhea in adults. Its key clinical late-stage development programs include RHB-104 for Crohn's disease; RHB-204, for pulmonary nontuberculous mycobacteria infections; RHB-102 (Bekinda) with positive results from a first Phase 3 study for acute gastroenteritis and gastritis; Opaganib (Yeliva); RHB-106, an encapsulated bowel preparation and RHB-107, a Phase 2-stage serine protease inhibitor targeting cancer and inflammatory gastrointestinal diseases.